Experimental Alnylam drug hits mark in late-stage study, lifting shares

Alnylam Pharmaceuticals said Wednesday that its lead experimental drug for a rare disease had passed a late-stage trial, adding more than $1.5 billion to the Cambridge company ’s market cap in pre-market trading and potentially paving the way for a first-of-its-kind treatment to hit the market. Alnylam (Nasdaq: ALNY) said that the Phase 3 study of patisiran, which targets a disease called amyloidosis ­that affects around 10,000 people, had met all of its goals. Import antly, the company and its…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news